Palivizumab for prevention of serious lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV) in infants at high risk of RSV disease

The South Australian Medicines Evaluation Panel evaluation summary for Rituximab (Refractory inflammatory myositis)

Download